Zobrazeno 1 - 10
of 141
pro vyhledávání: '"Damnernsawad A"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Shomali, William *, Damnernsawad, Alisa *, Theparee, Talent, Sampson, David, Morrow, Quinlan, Yang, Fei, Fernandez-Pol, Sebastian, Press, Richard, Zehnder, James, Tyner, Jeffrey W. *, Gotlib, Jason *
Publikováno v:
In Blood Advances 28 September 2021 5(18):3581-3586
Autor:
Edwards, David K., V, Watanabe-Smith, Kevin, Rofelty, Angela, Damnernsawad, Alisa, Laderas, Ted, Lamble, Adam, Lind, Evan F., Kaempf, Andy, Mori, Motomi, Rosenberg, Mara, d'Almeida, Amanda, Long, Nicola, Agarwal, Anupriya, Sweeney, David Tyler, Loriaux, Marc, McWeeney, Shannon K., Tyner, Jeffrey W. *
Publikováno v:
In Blood 7 February 2019 133(6):588-599
Autor:
Xiaona You, Myung-Jeom Ryu, Eunjin Cho, Yanzhi Sang, Alisa Damnernsawad, Yun Zhou, Yangang Liu, Jing Zhang, Youngsook Lee
Publikováno v:
Frontiers in Cell and Developmental Biology, Vol 9 (2021)
Ras proteins control a complex intracellular signaling network. Gain-of-function mutations in RAS genes lead to RASopathy disorders in humans, including Noonan syndrome (NS). NS is the second most common syndromic cause of congenital heart disease. A
Externí odkaz:
https://doaj.org/article/61616fac3a9d456fa2f6b16adf00e978
Autor:
Alisa Damnernsawad, Daniel Bottomly, Stephen E. Kurtz, Christopher A. Eide, Shannon K. McWeeney, Jeffrey W. Tyner, Tamilla Nechiporuk
Publikováno v:
Haematologica, Vol 107, Iss 1 (2020)
Drug resistance impedes the long-term effect of targeted therapies in acute myeloid leukemia (AML), necessitating the identification of mechanisms underlying resistance. Approximately 25% of AML patients carry FLT3 mutations and develop post-treatmen
Externí odkaz:
https://doaj.org/article/77ae0d83a6244d158ead1609052ab16a
Autor:
Su Lin Lim, Alisa Damnernsawad, Pavithra Shyamsunder, Wee Joo Chng, Bing Chen Han, Liang Xu, Jian Pan, Dakle Pushkar Pravin, Serhan Alkan, Jeffrey W. Tyner, H. Phillip Koeffler
Publikováno v:
Haematologica, Vol 104, Iss 6 (2019)
Proteolysis targeting chimeric molecule ARV 825 causes ubiquitination of bromodomains resulting in their efficient degradation by proteasome activity. Bromodomain degradation down-regulates MYC transcription contributing to growth inhibition of vario
Externí odkaz:
https://doaj.org/article/9021855a10e84e4687b818197b0e2f3b
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Sara J. C. Gosline, Cristina Tognon, Michael Nestor, Sunil Joshi, Rucha Modak, Alisa Damnernsawad, Camilo Posso, Jamie Moon, Joshua R. Hansen, Chelsea Hutchinson-Bunch, James C. Pino, Marina A. Gritsenko, Karl K. Weitz, Elie Traer, Jeffrey Tyner, Brian Druker, Anupriya Agarwal, Paul Piehowski, Jason E. McDermott, Karin Rodland
Publikováno v:
Clinical Proteomics. 19
Acute Myeloid Leukemia (AML) affects 20,000 patients in the US annually with a five-year survival rate of approximately 25%. One reason for the low survival rate is the high prevalence of clonal evolution that gives rise to heterogeneous sub-populati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f475d159347baf431a4b1e8c5e2e9284
https://doi.org/10.1186/s12014-022-09367-9
https://doi.org/10.1186/s12014-022-09367-9
Autor:
Christopher A. Eide, Stephen E. Kurtz, Shannon K. McWeeney, Tamilla Nechiporuk, Daniel Bottomly, Alisa Damnernsawad, Jeffrey W. Tyner
Publikováno v:
Haematologica. 107:77-85
Drug resistance impedes the long-term effect of targeted therapies in acute myeloid leukemia (AML), necessitating the identification of mechanisms underlying resistance. Approximately 25% of AML patients carry FLT3 mutations and develop post-treatmen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::25b7fdefc1dc262b2aefadd2478d55c4
https://doi.org/10.3324/haematol.2020.257964
https://doi.org/10.3324/haematol.2020.257964
Kras-Deficient T Cells Attenuate Graft-versus-Host Disease but Retain Graft-versus-Leukemia Activity
Autor:
Alisa Damnernsawad, Juan C. Felix, Yuhong Chen, Renren Wen, Chunji Gao, Guoping Fu, Robert Burns, Christopher P. Hartley, Demin Wang, Yongwei Zheng, Jing Zhang, Lan Luo, Mei Yu, Xiao Chen, Wen Zhu, Vivian Zhou, Williams R Drobyski
Publikováno v:
J Immunol
Acute graft-versus-host disease (aGVHD) is one major serious complication that is induced by alloreactive donor T cells recognizing host Ags and limits the success of allogeneic hematopoietic stem cell transplantation. In the current studies, we iden
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::399898dcf0e7841d61784918f7bc7196
https://doi.org/10.4049/jimmunol.2000006
https://doi.org/10.4049/jimmunol.2000006